Clinical Trials Sponsored by Novo Nordisk

Total 2937 results

Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada, Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations (CHOICE)

Menopause | Menopausal Vasomotor Symptoms

Denmark, United Kingdom, Sweden, Belgium, Switzerland, Germany, France, Finland, Austria, Norway
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Malaysia, South Africa, Hong Kong, Taiwan, Philippines
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes (LIRA-LIXI™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France, Finland, Germany, Hungary, Latvia, Lithuania, Italy, Czech Republic
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Menopause | Postmenopausal Vaginal Atrophy

Germany
Novo Nordisk A/S

Completed

Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes (REMIND™)

Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

Israel, Canada, Sweden, Finland
Novo Nordisk A/S

Completed

Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark
Novo Nordisk A/S

Completed

Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control (LIGHT)

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan

Healthy | Diabetes

Taiwan
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes (PREDICTIVE™)

Diabetes Mellitus, Type 2 | Diabetes

Sweden
Novo Nordisk A/S

Completed

Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes (PREDICTIVE™)

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Novo Nordisk A/S

Completed

Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark, Croatia, Australia, South Africa, Italy, Sweden
Novo Nordisk A/S

Completed

Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Australia
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Netherlands, France, Slovakia
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Healthy | Diabetes

Hungary
Novo Nordisk A/S

Completed

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding Disorder | Haemophilia B

United States, Sweden, Spain, Germany, United Kingdom, Denmark, France, Japan
Novo Nordisk A/S

Completed

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Evaluating the Use of Two Different Needles in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Glycemic Control Achieved With 2 Different Needles

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

United States
Novo Nordisk A/S

Completed

Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

Italy, United Kingdom, Austria, Netherlands, Germany
Novo Nordisk A/S

Completed

Diabetes Attitudes Wishes and Needs (DAWN2)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare Professionals

Spain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
Novo Nordisk A/S

Completed

French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients (DIALOG)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

France
Novo Nordisk A/S

Completed

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India (DiabCare India)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

Foetal Growth Problem | Small for Gestational Age

Netherlands
Novo Nordisk A/S

Completed

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

India, Morocco, South Africa, Oman
Novo Nordisk A/S

Completed

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

Turner Syndrome | Genetic Disorder

Netherlands
Novo Nordisk A/S

Completed

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France
Novo Nordisk A/S

Completed

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Diabetes Mellitus, Type 2 | Diabetes

Morocco, Tunisia, Algeria, South Africa, Egypt
Novo Nordisk A/S

Completed

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States

Clinical Trials Sponsored by Novo Nordisk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations